Tue, Aug 13, 2019 - Page 7 News List

No-deal Brexit could deepen Europe’s shortage of medicine, experts say

HEALTH RISK:The UK exported about US$14.5 billion worth of medicines in 2016, and a disorderly withdrawal could disrupt supplies in the bloc, health experts say


A pro-Brexit demonstrator holds a British flag with the words “Leave Means Leave” in front of the Winston Churchill statue in London on March 29.

Photo: AP

As the Oct. 31 deadline for Britain to leave the EU approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit.

Britain’s food and drink lobby last week said that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.

Pharmaceutical companies have expressed similar concerns about medicines, and some have reserved air freight capacity to fly in supplies if needed. .

However, the impact on medical supplies will also be felt beyond Britain. About 45 million packs of medicines are shipped from Britain to the rest of the bloc every month, in trade worth nearly £12 billion (US$14.5 billion) in 2016, a British parliament report said.

Experts say some disruption is inevitable if Britain leaves the EU without a deal. British Prime Minister Boris Johnson has said he will lead his country out of the EU on Oct. 31 without a deal if the bloc refuses to negotiate a new divorce agreement.

Some drugs might not have the required regulatory approval by then to continue being brought in from Britain. About 1 billion packs go in one direction or the other each year, industry data show.

Increased customs controls at ports and other borders between Britain and the EU could also disrupt supplies of drugs and the chemical compounds needed to produce them, regulators and industry representatives say.

“Despite intensive preparation by industry for every scenario, a no-deal Brexit risks disruption to the supply of medicines” throughout the EU, European Federation of Pharmaceutical Industries and Associations communications director Andy Powrie-Smith said.

The EU drugs regulator, the European Medicines Agency (EMA), said the bloc is well prepared for Brexit and has finalized authorisations for nearly all the 400 drugs under its watch that required further clearing because of Britain’s impending departure.

However, authorization is pending for three medicines that need EU-wide licences, an EMA official said without identifying them.

Other essential medicines could also be blocked because of supervisory hurdles because of Brexit, EMA data show.

The agency is the only body that can authorize sales in the 28-country EU of new drugs to treat the most common and serious diseases, including cancer, diabetes and flu.

Many other medicines authorized at national level could also be at risk. Nearly 6,000 of these drugs need to go through a new licensing process after Brexit.

The EMA official said the agency did not have “a full picture” of the situation in all EU states for nationally authorized medicines.

The Netherlands in February said that 50 “critical” drugs were at risk of shortages in the event of a no-deal Brexit.

Concerns about most of those drugs have since been resolved, a spokesman for the Dutch Ministry of Health, Welfare and Sport said, but problems could arise for less essential medicines.

In a report in June, the European Commission included medicines and medical devices in a list of sectors for which “continued and particular vigilance” was needed.

Many EU states already face shortages of some medicines because of problems with production, regulators or distribution.

A survey of 21 European countries showed that all of them experienced shortages of medicines last year, said Pharmaceutical Group of the EU, a pharmacists’ trade body. Vaccines were among the drugs most frequently cited as being in short supply.

This story has been viewed 1469 times.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top